16-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with Cardiac Hypertrophy in 1 studies
*Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alqahtani, MA; El-Ghiaty, MA; El-Kadi, AOS; Hidayat, R; Shoieb, SM | 1 |
1 other study(ies) available for 16-hydroxy-5,8,11,14-eicosatetraenoic acid and Cardiac Hypertrophy
| Article | Year |
|---|---|
The Effects of 16-HETE Enantiomers on Hypertrophic Markers in Human Fetal Ventricular Cardiomyocytes, RL-14 Cells.
Topics: Cardiomegaly; Humans; Hydroxyeicosatetraenoic Acids; Luciferases; Myocytes, Cardiac; RNA, Messenger | 2023 |